CCR5 and tick-borne encephalitis: Overall, these findings together with the data reported for in vivo (clinical trials) and in vitro (laboratory findings) studies support the view that CCR5 could represent an excellent target to fight HIV and a good alternative to classical antiviral approaches, although it should be taken into account the concomitant geographical location of CCR5Δ32 and other pathologies, such as West Nile infection or tick-borne encephalitis.